ReviewBlood2013
Hematopoietic specification from human pluripotent stem cells: current advances and challenges toward de novo generation of hematopoietic stem cells.
Review in Blood, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
83 citing papers in PubMed.
- Retinoic acid as a stage-specific modulator of hematopoietic lineage fate from human pluripotent stem cells.Cell communication and signaling : CCS · 2026Article
- Article
- Temporal Regulation of Cytokines and Growth Factors for Optimized Hematopoietic-Lineage Specification from Human Pluripotent Stem Cells.International journal of stem cells · 2025Article
- ELTD1 inhibits differentiation of hemogenic endothelium progenitors from human embryonic stem cells through the HPIP-Wnt pathway.Experimental & molecular medicine · 2025Article
- Immunoregulatory iPSC-derived non-lymphoid progeny in autoimmunity and GVHD alloimmunity.Stem cells (Dayton, Ohio) · 2025Review
- Article
- Improving hematopoietic differentiation from human induced pluripotent stem cells by the modulation of Hippo signaling with a diarylheptanoid derivative.Stem cell research & therapy · 2024Article
- Identification and characterization of human hematopoietic mesoderm.Science China. Life sciences · 2024Article
- Emerging Models to Study Human Microglia In vitro.Advances in neurobiology · 2024Review
- Article
- Self-organized yolk sac-like organoids allow for scalable generation of multipotent hematopoietic progenitor cells from induced pluripotent stem cells.Cell reports methods · 2023Article
- In vitro vascular differentiation system efficiently produces natural killer cells for cancer immunotherapies.Oncoimmunology · 2023Article
- Lateral plate mesoderm cell-based organoid system for NK cell regeneration from human pluripotent stem cells.Cell discovery · 2022Article
- Hypoxia drives hematopoiesis with the enhancement of T lineage through eliciting arterial specification of hematopoietic endothelial progenitors from hESC.Stem cell research & therapy · 2022Article
- Genetic correction of concurrent α- and β-thalassemia patient-derived pluripotent stem cells by the CRISPR-Cas9 technology.Stem cell research & therapy · 2022Article
- Vascular endothelial growth factor c regulates hematopoietic stem cell fate in the dorsal aorta.Development (Cambridge, England) · 2022Article
- Leukemic Stem Cell: A Mini-Review on Clinical Perspectives.Frontiers in oncology · 2022Review
- Generation of a H9 Clonal Cell Line With Inducible Expression of NUP98-KDM5A Fusion Gene in the AAVS1 Safe Harbor Locus.Frontiers in cell and developmental biology · 2022Article
- Review
- Progress in the production of haematopoietic stem and progenitor cells from human pluripotent stem cells.Journal of immunology and regenerative medicine · 2021Article
23 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Significant advances in cellular reprogramming technologies and hematopoietic differentiation from human pluripotent stem cells (hPSCs) have already enabled the routine production of multiple lineages of blood cells in vitro and opened novel opportunities to study hematopoietic development, model genetic blood diseases, and manufacture immunologically matched cells for transfusion and cancer immunotherapy. However, the generation of hematopoietic cells with robust and sustained multilineage engraftment has not been achieved. Here, we highlight the recent advances in understanding the molecular and cellular pathways leading to blood development from hPSCs and discuss potential approaches that can be taken to facilitate the development of technologies for de novo production of hematopoietic stem cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.